Rosalind Advisors, Inc.
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed April 25, 2024), Rosalind Advisors, Inc. reported 31 stock positions worth $106.9 million. Its top holding was Myomo (MYO) at 7.5% of the portfolio, followed by Lyra Therapeutics (LYRA, 6.7%) and Mediwound (MDWD, 6.5%). Compared with Q4 2023, it opened 11 new positions, sold out of 7, added to 2 and reduced 11. The biggest buy was a new position in Cybin and the biggest sale an exit from Astria Therapeutics (ATXS).
- Most Recent 13F
- Q2 2026
- Location
- TORONTO, A6
- CIK
- 0001622627
- Portfolio Value
- $106.9M (Q1 2024)
- SEC Filing
- 0001622627-24-000021 ↗ filed Apr 25, 2024
Holdings Value
Holdings 31 stocks · $106.9M
| MYO Myomo Inc. | 7.48% | 2,447,740 | $8.0M | Add +27.5% |
| LYRA Lyra Therapeutics Inc. | 6.66% | 1,144,524 | $7.1M | Reduce -39.4% |
| MDWD Mediwound Ltd. | 6.48% | 485,990 | $6.9M | Reduce -19.9% |
| OPTINOSE INC | 6.20% | 4,541,489 | $6.6M | Reduce -7.0% |
| XERS Xeris Biopharma Holdings Inc. | 5.83% | 2,820,170 | $6.2M | Reduce -20.4% |
| CMPS Compass Pathways PLC | 5.71% | 734,000 | $6.1M | Reduce -8.1% |
| CYBIN INC | 5.40% | 13,960,000 | $5.8M | New |
| ABVX Abivax SA-ADR | 5.06% | 378,416 | $5.4M | New |
| VRDN Viridian Therapeutics Inc. | 4.91% | 300,000 | $5.3M | Reduce -16.7% |
| DCTH Delcath Systems Inc. | 4.63% | 1,038,828 | $5.0M | No change |
| PROF Profound Medical Corp. | 4.25% | 533,333 | $4.5M | No change |
| VRNA Verona Pharma Ltd. | 3.76% | 250,000 | $4.0M | No change |
| CLEARSIDE BIOMEDICAL INC | 3.71% | 2,592,593 | $4.0M | New |
| OTLK Outlook Therapeutics Inc. | 3.48% | 311,775 | $3.7M | New |
| KALV Kalvista Pharmaceuticals Inc. | 3.19% | 287,985 | $3.4M | Reduce -4.0% |
| TRVI Trevi Therapeutics Inc. | 2.99% | 926,016 | $3.2M | Reduce -50.3% |
| VERU Veru Inc. | 2.95% | 4,500,000 | $3.2M | Add +12.5% |
| UNICYCIVE THERAPEUTICS INC | 2.43% | 1,879,646 | $2.6M | New |
| CLRB Cellectar Biosciences Inc. | 2.31% | 621,478 | $2.5M | Reduce -69.0% |
| PYPD Polypid Ltd. | 1.79% | 415,800 | $1.9M | New |
| NSPR Inspiremd Inc. | 1.52% | 686,062 | $1.6M | Reduce -25.9% |
| KPRX Kiora Pharmaceuticals Inc. | 1.52% | 2,300,000 | $1.6M | New |
| XAIR Beyond Air Inc. | 1.47% | 903,614 | $1.6M | New |
| TVRD Cara Therapeutics Inc. | 1.32% | 1,548,893 | $1.4M | New |
| FBIO Fortress Biotech Inc. | 1.14% | 607,797 | $1.2M | No change |
| SPRB Spruce Biosciences Inc. | 1.11% | 1,508,419 | $1.2M | Reduce -4.9% |
| TLPH Talphera Inc. | 0.73% | 758,966 | $782K | No change |
| BFRI Biofrontera Inc. | 0.73% | 504,261 | $777K | New |
| GERN Geron Corp. | 0.62% | 200,000 | $660K | No change |
| RZLT Rezolute Inc. | 0.48% | 200,000 | $510K | New |
| TNXP Tonix Pharmaceuticals Holdin | 0.16% | 900,900 | $168K | No change |
Options reported separately and not counted above: XBI puts ($73K), INVESCO QQQ TR puts ($7K), AMYLYX PHARMACEUTICALS INC calls ($0).
Portfolio Sells Q4 2023 → Q1 2024
| ATXS Astria Therapeutics Inc. | Sold out | 0.00% | −7.25 |
| MDGL Madrigal Pharmaceuticals Inc. | Sold out | 0.00% | −4.84 |
| SRPT Sarepta Therapeutics Inc. | Sold out | 0.00% | −4.63 |
| SPRB Spruce Biosciences Inc. | Reduce -4.9% | 1.11% | −2.78 |
| CLRB Cellectar Biosciences Inc. | Reduce -69.0% | 2.31% | −2.34 |
| ASND Ascendis Pharma A/S | Sold out | 0.00% | −1.77 |
| VRDN Viridian Therapeutics Inc. | Reduce -16.7% | 4.91% | −1.65 |
| LYRA Lyra Therapeutics Inc. | Reduce -39.4% | 6.66% | −1.62 |
| NVNO Envveno Medical Corporation | Sold out | 0.00% | −1.34 |
| XERS Xeris Biopharma Holdings Inc. | Reduce -20.4% | 5.83% | −1.14 |
| REVIVA PHARMACEUTCLS HLDGS I | Sold out | 0.00% | −0.85 |
| MACK Merrimack Pharmaceuticals Inc. | Sold out | 0.00% | −0.67 |
| NSPR Inspiremd Inc. | Reduce -25.9% | 1.52% | −0.65 |
| CMPS Compass Pathways PLC | Reduce -8.1% | 5.71% | −0.14 |
| KALV Kalvista Pharmaceuticals Inc. | Reduce -4.0% | 3.19% | +0.12 |
| TRVI Trevi Therapeutics Inc. | Reduce -50.3% | 2.99% | +0.90 |
| OPTINOSE INC | Reduce -7.0% | 6.20% | +0.93 |
| MDWD Mediwound Ltd. | Reduce -19.9% | 6.48% | +1.31 |
Portfolio Buys Q4 2023 → Q1 2024
| CYBIN INC | New | 5.40% | +5.40 |
| ABVX Abivax SA-ADR | New | 5.06% | +5.06 |
| CLEARSIDE BIOMEDICAL INC | New | 3.71% | +3.71 |
| OTLK Outlook Therapeutics Inc. | New | 3.48% | +3.48 |
| UNICYCIVE THERAPEUTICS INC | New | 2.43% | +2.43 |
| PYPD Polypid Ltd. | New | 1.79% | +1.79 |
| KPRX Kiora Pharmaceuticals Inc. | New | 1.52% | +1.52 |
| XAIR Beyond Air Inc. | New | 1.47% | +1.47 |
| TVRD Cara Therapeutics Inc. | New | 1.32% | +1.32 |
| BFRI Biofrontera Inc. | New | 0.73% | +0.73 |
| VERU Veru Inc. | Add +12.5% | 2.95% | +0.54 |
| RZLT Rezolute Inc. | New | 0.48% | +0.48 |
| MYO Myomo Inc. | Add +27.5% | 7.48% | −0.56 |
Options Activity Q4 2023 → Q1 2024
| SAREPTA THERAPEUTICS INC | put | Sold out | 57,400 | $832Kbefore exit |
| XBI SS SPDR S&P Biotech ETF | put | Reduce -90.0% | 50,000 | $73K |
| INVESCO QQQ TR | put | Reduce -88.9% | 100,000 | $7K |
| AMYLYX PHARMACEUTICALS INC | call | New | 50,000 | $0 |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 29 | $266.2M | DCTH, FENC, XERS, SVRA, VSTM |
| Q1 2026 | 32 | $244.1M | DCTH, XERS, FENC, SVRA, PCVX |
| Q4 2025 | 29 | $274.5M | DCTH, SVRA, FENC, XERS, VRDN |
| Q3 2025 | 29 | $283.0M | DCTH, CYTK, FENC, VSTM, RZLT |
| Q2 2025 | 29 | $206.6M | DCTH, FENC, CYTK, OCUL, IDYA |
| Q1 2025 | 31 | $205.2M | DCTH, VSTM, XERS, MYO, IDYA |
| Q4 2024Amended | 28 | $185.7M | DCTH, MYO, MDWD, CMRX, XERS |
| Q3 2024 | 29 | $150.7M | DCTH, MYO, CRMD, ABEO, MDWD |
| Q2 2024 | 35 | $126.5M | DCTH, MYO, MDWD, OPTINOSE INC, ABEO |
| Q1 2024 | 31 | $106.9M | MYO, LYRA, MDWD, OPTINOSE INC, XERS |